|
1
|
Chen R, Zhang D, Mao Y, Zhu J, Ming H, Wen
J, Ma J, Cao Q, Lin H, Tang Q, Liang J and Feng Z: A human
Fab-based immunoconjugate specific for the LMP1 extracellular
domain inhibits nasopharyngeal carcinoma growth in vitro and
in vivo. Mol Cancer Ther. 11:594–603. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Young LS, Dawson CW, Clark D, Rupani H,
Busson P, Tursz T, Johnson A and Rickinson AB: Epstein-Barr virus
gene expression in nasopharyngeal carcinoma. J Gen Virol.
69:1051–1065. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brooks L, Yao QY, Rickinson AB and Young
LS: Epstein-Barr virus latent gene transcription in nasopharyngeal
carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts.
J Virol. 66:2689–2697. 1992.PubMed/NCBI
|
|
4
|
Jiwa NM, Oudejans JJ, Dukers DF, Vos W,
Horstman A, van der Valk P, Middledorp JM, Walboomers JM and Meijer
CJ: Immunohistochemical demonstration of different latent membrane
protein-1 epitopes of Epstein-Barr virus in lymphoproliferative
diseases. J Clin Pathol. 48:438–442. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Barnes L, Eveson JW, Reichart P and
Sidransky D; World Health Organization Classification of Tumours:
Pathology and Genetics of Head and Neck Tumours. IARC Press; Lyon:
pp. 81–105. 2005
|
|
6
|
Mao Y, Zhang DW, Wen J, Cao Q, Chen RJ,
Zhu J and Feng ZQ: A novel LMP1 antibody synergizes with mitomycin
C to inhibit nasopharyngeal carcinoma growth in vivo through
inducing apoptosis and downregulating vascular endothelial growth
factor. Int J Mol Sci. 13:2208–2218. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mao Y, Zhang DW, Zhu H, Lin H, Xiong L,
Cao Q, Liu Y, Li QD, Xu JR, Xu LF and Chen RJ: LMP1 and LMP2A are
potential prognostic markers of extranodal NK/T-cell lymphoma,
nasal type (ENKTL). Diagn Pathol. 7:1782012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mao Y, Zhang DW, Lin H, Xiong L, Liu Y, Li
QD, Ma J, Cao Q, Chen RJ, Zhu J and Feng ZQ: Alpha B-crystallin is
a new prognostic marker for laryngeal squamous cell carcinoma. J
Exp Clin Cancer Res. 31:1012012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pan LX, Diss TC, Peng HZ and Isaacson PG:
Clonality analysis of defined B-cell populations in archival tissue
sections using microdissection and the polymerase chain reaction.
Histopathology. 24:323–327. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zeng W, Zhou M and Lin H: The significance
of detecting Epstein-Barr virus BNLF1 fragment and its expression
in Hodgkin’s disease in the Guangdong area. Zhonghua Bing Li Xue Za
Zhi. 26:27–30. 1997.In Chinese.
|
|
11
|
QingLing Z, LiNa Y, Li L, Shuang W, YuFang
Y, Yi D, Divakaran J, Xin L and YanQing D: LMP1 antagonizes
WNT/β-catenin signalling through inhibition of WTX and promotes
nasopharyngeal dysplasia but not tumourigenesis in LMP1 (B95-8)
transgenic mice. J Pathol. 223:574–583. 2011.PubMed/NCBI
|
|
12
|
Kieff E and Rickinson AB: Epstein-Barr
virus and its replication. Field’s Virology. Knipe M and Howley PM:
4th edition. Lippincott Williams & Wilkins; Philadelphia, PA:
pp. 2511–2627. 2001
|
|
13
|
Wilson JB, Weinberg W, Johnson R, Yuspa S
and Levine AJ: Expression of the BNLF-1 oncogene of Epstein-Barr
virus in the skin of transgenic mice induces hyperplasia and
aberrant expression of keratin 6. Cell. 61:1315–1327. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kulwichit W, Edwards RH, Davenport EM,
Baskar JF, Godfrey V and Raab-Traub N: Expression of the
Epstein-Barr virus latent membrane protein 1 induces B cell
lymphoma in transgenic mice. Proc Natl Acad Sci USA.
95:11963–11968. 1998. View Article : Google Scholar
|
|
15
|
Stevenson D, Charalambous C and Wilson JB:
Epstein-Barr virus latent membrane protein 1 (CAO) up-regulates
VEGF and TGF alpha concomitant with hyperlasia, with subsequent
up-regulation of p16 and MMP9. Cancer Res. 65:8826–8835. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gennari F, Mehta S, Wang Y, St Clair
Tallarico A, Palu G and Marasco WA: Direct phage to intrabody
screening (DPIS): demonstration by isolation of cytosolic
intrabodies against the TES1 site of Epstein Barr virus latent
membrane protein 1 (LMP1) that block NF-kappaB transactivation. J
Mol Biol. 335:193–207. 2004. View Article : Google Scholar
|
|
17
|
Fang CY, Chang YS, Chow KP, Yu JS and
Chang HY: Construction and characterization of monoclonal
antibodies specific to Epstein-Barr virus latent membrane protein
1. J Immunol Methods. 287:21–30. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Piché A, Kasono K, Johanning F, Curiel TJ
and Curiel DT: Phenotypic knock-out of the latent membrane protein
1 of Epstein-Barr virus by an intracellular single-chain antibody.
Gene Ther. 5:1171–1179. 1998.PubMed/NCBI
|
|
19
|
Salamon D, Adori M, Ujvari D, Wu L, Kis
LL, Madapura HS, Nagy N, Klein G and Klein E: Latency
type-dependent modulation of Epstein-Barr virus-encoded latent
membrane protein 1 expression by type I interferons in B cells. J
Virol. 86:4701–4707. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ning S, Hahn AM, Huye LE and Pagano JS:
Interferon regulatory factor 7 regulates expression of Epstein-Barr
virus latent membrane protein 1: a regulatory circuit. J Virol.
77:9359–9368. 2003. View Article : Google Scholar : PubMed/NCBI
|
